HOVON 143 (FL)

HOVON 143 (FL)

Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma (MM) patients; an open-label phase II trial (HOVON 143)

Study treatments

Inclusion criteria

Exclusion criteria

Participating sites